As expected, DC–Lysate and DC–Pool Peptide vaccines (containing both tumor and PVEC antigens) were effective in eliciting/recruiting CD8+ TILs capable of recognizing both B16 melanoma cells and tumor-associated PVECs; however, this was also true to a variable degree for vaccines selectively targeting tumor- or PVEC-associated antigens. The gene discussed is CD8A; the disease is melanoma.